Skip to main content

X4 Pharmaceuticals, Inc

XFOR
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001501697

In the last 90 days, X4 Pharmaceuticals, Inc insiders filed 0 open-market purchases and 3 sales; 89 institutions reported holding it in 13F filings for Q2 2026, worth $463.0M in total; no superinvestor holds it.

Q3 2021 vs. Q2 2021

How the institutions holding X4 Pharmaceuticals, Inc changed between Q2 2021 and Q3 2021.

All holders in Q3 2021All holders in Q2 2021

13F holders of XFOR: Q2 2021 compared with Q3 2021
MeasureQ2 2021Q3 2021Change
Holders6352−11
Shares16.6M16.2M−381.2K (−2.3%)
Value$107.8M$85.7M−$22.0M (−20.5%)

New holders (6)

Institutions that held X4 Pharmaceuticals, Inc at the end of Q3 2021 but not at the end of Q2 2021.

Institutions new to XFOR in Q3 2021
InstitutionSharesValue% of portfolio
Altium Capital Management LP804,598$4.26M1.14%
Norges Bank27,700$147.0K0.00%
Marshall Wace North America L.P.26,252$139.0K0.00%
American Portfolios Advisors6,250$33.1K0.00%
Group One Trading, L.P.2,083$11.0K0.00%
IFP Advisors, Inc1,000$5.00K0.00%

Sold out (17)

Institutions that held X4 Pharmaceuticals, Inc at the end of Q2 2021 and filed for Q3 2021 without it.

Institutions that sold out of XFOR in Q3 2021
InstitutionShares, Q2 2021Value, Q2 2021
Abingworth LLP229,885$1.49M
Prosight Management, LP87,813$571.0K
Jane Street Group, LLC71,670$466.0K
Endurant Capital Management LP70,969$461.0K
ExodusPoint Capital Management, LP56,893$370.0K
Tibra Equities Europe Ltd48,400$315.0K
JPMorgan Chase & Co47,334$308.0K
Engineers Gate Manager LP21,814$142.0K
Squarepoint Ops LLC20,638$134.0K
Alpine Global Management, LLC16,877$110.0K
Cubist Systematic Strategies, LLC13,135$85.0K
LMR Partners LLP10,152$66.0K
Royal Bank of Canada2,064$13.0K
Panagora Asset Management Inc1,060$7.00K
New York State Common Retirement Fund134$1.00K
UBS Group AG122$1.00K
Citigroup Inc25$0